MARKET

APRE

APRE

Aprea Therapeutics, Inc.
NASDAQ
0.7608
-0.0189
-2.42%
Closed 17:41 09/25 EDT
OPEN
0.7800
PREV CLOSE
0.7797
HIGH
0.7803
LOW
0.7414
VOLUME
53.34K
TURNOVER
0
52 WEEK HIGH
1.690
52 WEEK LOW
0.5480
MARKET CAP
9.58M
P/E (TTM)
-0.7069
1D
5D
1M
3M
1Y
5Y
1D
Aprea Therapeutics Announces Abstract Featuring Updated Interim Results From The Ongoing Phase 1 ACESOT-1051 Study Of Its WEE1 Inhibitor APR-1051 In Patients With Advanced Solid Tumors Has Been Accepted For Oral Presentation At The Symposium On Molecular Targets And Cancer Therapeutics
Benzinga · 5d ago
Weekly Report: what happened at APRE last week (0914-0918)?
Weekly Report · 09/21 09:06
Weekly Report: what happened at APRE last week (0907-0911)?
Weekly Report · 09/14 09:07
Weekly Report: what happened at APRE last week (0831-0904)?
Weekly Report · 09/07 09:06
Weekly Report: what happened at APRE last week (0824-0828)?
Weekly Report · 08/31 09:07
Aprea Expands Patent Portfolio For Precision Oncology Programs
NASDAQ · 08/28 15:55
Aprea Therapeutics Expands Global IP for Precision Oncology
TipRanks · 08/28 13:37
Aprea Therapeutics provides update on existing patent portfolio
TipRanks · 08/28 12:20
More
About APRE
Aprea Therapeutics, Inc. is a clinical-stage biopharmaceutical company focused on precision oncology through synthetic lethality. The Company’s pipeline includes two clinical-stage synthetic lethality programs. Its lead programs are APR-1051, an oral, small-molecule inhibitor of WEE1 kinase, and ATRN-119, a small-molecule ATR inhibitor, both in clinical development for solid tumor indications. Its ATRN-119 is an oral small molecule inhibitor of ataxia telangiectasia and Rad3-related (ATR). The ATR kinase is a master regulator of Deoxyribonucleic Acid (DNA) damage response, with roles in cell cycle control and DNA repair following replication stress. It is evaluating potential combination opportunities within its pipeline, including research on the combination of ATRN-119 and APR-1051 that is supported by a Phase II SBIR grant from the National Cancer Institute. It also has an early-stage program, in the lead optimization stage, for an undisclosed DNA-damage response (DDR) target.

Webull offers Aprea Therapeutics Inc stock information, including NASDAQ: APRE real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, APRE stock news, and many more online research tools to help you make informed decisions. Trade stocks for 0 commission and 0 contract fees on the web version for easy and convenient access, or download the Webull app and trade on the go.

You can practice and explore trading APRE stock methods without spending real money on the virtual paper trading platform.